Compare ResMed Inc. (RMD) vs Tencent Music Entertainment Group - ADR (TME) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Tencent Music Entertainment Group - ADR — how do they compare? ResMed Inc. trades at $219.5 (market cap $31.73B), while Tencent Music Entertainment Group - ADR trades at $7.9 (market cap $13.10B). The key difference: ResMed Inc. is far larger — about 2.4× Tencent Music Entertainment Group - ADR's market cap, and Tencent Music Entertainment Group - ADR pays the higher dividend (3.04%). Which is the better fit depends on your goals.
| RMD | TME | |
|---|---|---|
Market Cap | $31.73B | $13.10B |
Sector | Health | Media |
52-Week High | $283.28 | $26.36 |
52-Week Low | $182.82 | $7.89 |
Enterprise Value | $31.08B | $11.05B |
Dividend Yield | 1.2% | 3.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $221.05, down 3.2% on the day, with a bearish technical signal and key support at $218. The company reported strong Q4 2026 results, beating EPS estimates at $2.95, and maintains robust profitability with a 26.94% net income margin. Revenue growth remains solid, reaching $5.15B in 2025, though weak 2027 sales guidance has pressured the stock. A dividend of $0.66 is scheduled for payment in September 2026.
Outlook is mixed: strong fundamentals and a consensus price target of $235.70 suggest upside, but bearish technicals and investor lawsuits pose near-term risks. The stock offers value with a P/E of 21.19, yet competitive and regulatory challenges require monitoring for sustained growth.
Tencent Music Entertainment (TME) trades at $8.06, down 2.42% on the day, with technical indicators signaling a bearish trend. The company reported strong Q2 2026 earnings with an EPS beat of $0.25 versus $0.24 expected, and revenue growth to $32.9B in 2025. However, recent news highlights a $1 billion notes offering and mixed analyst sentiment amid competitive pressures.
TME presents a value opportunity with a low P/E of 9.46 and a consensus price target of $12.15, but faces risks from slowing growth and intense competition. Investors should weigh solid fundamentals against near-term headwinds in the music streaming sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Tencent Music Entertainment Group - ADR
TME is the largest online music service provider in China. It was founded in 2016 with the business combination of QQ Music (founded in 2005), Kuwo Music (founded in 2005) and Kugou Music (founded in 2004) streaming platforms. Tencent is the largest shareholder of TME with over 50% shares and over 90% voting rights held. TME also provides social entertainment services, including music live audio/video broadcasts and online concert services through the three platforms mentioned above, and online karaoke through an independent platform WeSing.
Read more on TME →
